Inclusion Criteria

Required:

• Documented HIV infection OR working diagnosis of HIV OR evidence of idiopathic suppression with an AIDS-defining opportunistic infection or malignancy (except Kaposi's sarcoma).
• CD4+ cell count = or < 200/mm3 or = or < 15 percent of total lymphocyte count within previous 90 days OR history of AIDS-defining opportunistic infection.
• Current PCP prophylaxis.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

• Symptoms of pancreatitis or peripheral neuropathy of grade 2 or worse.
• Requirement for acute therapy for any active AIDS-defining opportunistic infection or systemic chemotherapy for malignancy.
• Stage 2 or worse (moderate) AIDS Dementia Complex.
• Other disorders or conditions for which the study drugs are contraindicated or that may prevent adequate compliance with study therapy.

Concurrent Medication:

Excluded:

• Acute therapy for active AIDS-defining opportunistic infection.
• Systemic chemotherapy for malignancy.
• Antiretroviral therapy other than that provided by this study.

Patients with the following prior conditions are excluded:

• History of pancreatitis or peripheral neuropathy of grade 2 or worse.
• History of intolerance to the study drugs at entry doses and/or frequencies.
• History of phenylketonuria.